aflibercept – Patient Worthy

Clinical Trial Results Show Wet Age-Related Macular Degeneration Patients May Need Less Frequent Treatment

Post author:Trudy Horsting
Post published:March 7, 2022
Post category:Wet macular degeneration

Regeneron Pharmaceuticals has just announced the results from their Phase 2 trial of aflibercept. The trial aimed to compare an 8mg dose of the treatment to a 2mg dose, which…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More